Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis



Status:Recruiting
Conditions:Psoriasis, Dermatology, Dermatology, Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery
Healthy:No
Age Range:18 - Any
Updated:4/6/2019
Start Date:January 2, 2018
End Date:December 2019
Contact:Sara Penchev
Email:contact@bmxpharma.com
Phone:720-613-4872

Use our guide to learn which trials are right for you!

A Randomized, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety, Clinical Effects, and Systemic Exposure of a Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

This is a randomized, placebo-controlled Phase 2 trial consisting of up to 300 subjects with
either psoriasis or atopic dermatitis. In this trial BMX-010 will be topically applied twice
daily for up to 28 days.

This is a Phase 2, randomized, multicenter, placebo-controlled study sponsored by BioMimetix
JV, LLC (BMX). It is a double-blind parallel cohort study designed to determine the safety
and efficacy of BMX-010 (0.03%) relative to Placebo in subjects with atopic dermatitis and
psoriasis.

Subjects will be queried regarding adverse events (AEs) and concomitant medication usage.

Inclusion Criteria:

- Diagnosis of either atopic dermatitis or psoriasis with mild to moderate lesions
involving 1% - 25% of total body surface area

- Candidate for topical treatment of atopic dermatitis or psoriasis

- Negative pregnancy test for females of childbearing potential

Exclusion Criteria:

- Systemic pharmacotherapy or phototherapy for treatment of atopic dermatitis or
psoriasis

- Erythrodermic, guttate or generalized pustular psoriasis

- Treatment of systemic retinoids, corticosteroids or immunosuppressive agents within 4
weeks of baseline visit

- Treatment with high potency topical steroids, vitamin D analogs, keratolytics, coal
tar, phototherapy, calcineurin inhibitors, or antihistamines within 2 weeks of
baseline visit

- UV or Dead Sea therapy within 4 weeks of baseline visit

- Treatment with a biologic agent (monoclonal antibody) within 30 days or 5 times its
circulating half-life (whichever is longer) prior to baseline visit

- Atopic dermatitis triggered by environmental allergen or irritant

- Contact dermatitis or drug-induced skin reactions

- Systemic or skin infection requiring antimicrobial therapy

- Systemic chemotherapy or radiotherapy within 4 weeks of baseline visit

- Immunocompromise of any cause

- Pregnancy, lactation or inadequate contraception

- Active drug or alcohol dependence

- Significant acute or chronic medical, neurological or psychiatric illness that would
compromise subject's safety
We found this trial at
10
sites
Miami, Florida 33173
Principal Investigator: Giovanna Ciocca, MD
Phone: 305-273-7998
?
mi
from
Miami, FL
Click here to add this to my saved trials
125 Rampart Way
Denver, Colorado 80230
Phone: 303-261-1525
?
mi
from
Denver, CO
Click here to add this to my saved trials
Encino, California 91436
Principal Investigator: Tooraj Raoof, MD
?
mi
from
Encino, CA
Click here to add this to my saved trials
3701 South Clarkson Street
Englewood, Colorado 80113
Principal Investigator: Kimberly C Stone, MD
Phone: 303-740-4883
?
mi
from
Englewood, CO
Click here to add this to my saved trials
Greenwood Village, Colorado
Principal Investigator: Joel Cohen, MD
Phone: 303-756-7546
?
mi
from
Greenwood Village, CO
Click here to add this to my saved trials
Houston, Texas 77029
Principal Investigator: Julian Gonzalez, MD
Phone: 713-453-8328
?
mi
from
Houston, TX
Click here to add this to my saved trials
Indianapolis, Indiana 46256
Principal Investigator: Kenneth Dawes, MD
Phone: 317-621-7790
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Knoxville, Tennessee 37917
Principal Investigator: Edward Primka, MD
Phone: 865-524-2547
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Mount Pleasant, South Carolina 29464
Principal Investigator: Cynthia Strout, MD
Phone: 843-856-3784
?
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
New York, New York 10022
Principal Investigator: Bruce Katz, MD
Phone: 212-688-5882
?
mi
from
New York, NY
Click here to add this to my saved trials